July 14, 2022
Life Sciences
  • The Food and Drug Administration (FDA) authorized Novavax Inc.’s two-dose COVID-19 shot for emergency use for adults, putting Americans one step away from a fourth vaccine option. Novavax, whose COVID-19 vaccine is the first in the U.S. that uses traditional protein-based technology as opposed to mRNA, now awaits clearance from the Centers for Disease Control and Prevention. (Articles here, here, and here)